![Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements | Scientific Reports Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-63263-6/MediaObjects/41598_2020_63263_Fig1_HTML.png)
Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements | Scientific Reports
![PDF] Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. | Semantic Scholar PDF] Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3373dba5e016c74950f7ca66bc88adc348737a4a/7-Table3-1.png)
PDF] Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. | Semantic Scholar
![Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS. - ppt video online download Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS. - ppt video online download](https://slideplayer.com/8470909/26/images/slide_1.jpg)
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS. - ppt video online download
![Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS. - ppt video online download Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS. - ppt video online download](https://slideplayer.com/25/8052815/big_thumb.jpg)
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS. - ppt video online download
![MeMed Completes Trilogy of Clinical Studies with More Than 2,000 Patients Validating First Ever Blood Test to Accurately Distinguish Between Bacterial and Viral Infections MeMed Completes Trilogy of Clinical Studies with More Than 2,000 Patients Validating First Ever Blood Test to Accurately Distinguish Between Bacterial and Viral Infections](https://mma.prnewswire.com/media/451805/MeMed_Ltd_Logo.jpg?p=facebook)
MeMed Completes Trilogy of Clinical Studies with More Than 2,000 Patients Validating First Ever Blood Test to Accurately Distinguish Between Bacterial and Viral Infections
![A) TRILOGY study design. (B) TRINITY study design. Abbreviations: BDP,... | Download Scientific Diagram A) TRILOGY study design. (B) TRINITY study design. Abbreviations: BDP,... | Download Scientific Diagram](https://www.researchgate.net/publication/320274995/figure/tbl1/AS:668261020626963@1536337251921/Clinical-trials-with-triple-therapy-in-COPD_Q320.jpg)
A) TRILOGY study design. (B) TRINITY study design. Abbreviations: BDP,... | Download Scientific Diagram
![A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol - Respiratory A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol - Respiratory](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/20a3d2d4-4388-40b7-a5d7-5944052f842f/gr1_lrg.jpg)
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol - Respiratory
![JenaValve on Twitter: "JenaValve has successfully treated our 100th patient with Aortic Regurgitation using the Trilogy Heart Valve System. A special thank you to all of our ALIGN-AR Clinical Trial Sites for JenaValve on Twitter: "JenaValve has successfully treated our 100th patient with Aortic Regurgitation using the Trilogy Heart Valve System. A special thank you to all of our ALIGN-AR Clinical Trial Sites for](https://pbs.twimg.com/media/E5zKHsDVcAAZNxz.jpg:large)
JenaValve on Twitter: "JenaValve has successfully treated our 100th patient with Aortic Regurgitation using the Trilogy Heart Valve System. A special thank you to all of our ALIGN-AR Clinical Trial Sites for
![PDF] Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. | Semantic Scholar PDF] Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3373dba5e016c74950f7ca66bc88adc348737a4a/5-Figure2-1.png)
PDF] Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. | Semantic Scholar
![The Lancet on Twitter: "Single inhaler triple therapy for COPD - findings from the TRILOGY trial #ERSLDN2016 https://t.co/owtm3JsdkM https://t.co/TuqctwP3VC" / Twitter The Lancet on Twitter: "Single inhaler triple therapy for COPD - findings from the TRILOGY trial #ERSLDN2016 https://t.co/owtm3JsdkM https://t.co/TuqctwP3VC" / Twitter](https://pbs.twimg.com/media/CrVrQY-VIAAWiJu.jpg)
The Lancet on Twitter: "Single inhaler triple therapy for COPD - findings from the TRILOGY trial #ERSLDN2016 https://t.co/owtm3JsdkM https://t.co/TuqctwP3VC" / Twitter
![TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After... | tctmd.com TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After... | tctmd.com](https://d18mqtxkrsjgmh.cloudfront.net/public/styles/large_slide_teaser/public/2012-10/113852.png?itok=yxxTCRt-)
TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After... | tctmd.com
![Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease ( TRILOGY): a double-blind, parallel group, randomised controlled trial - The Lancet Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease ( TRILOGY): a double-blind, parallel group, randomised controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2066710324/2066792431/gr1.gif)
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease ( TRILOGY): a double-blind, parallel group, randomised controlled trial - The Lancet
![Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease ( TRILOGY): a double-blind, parallel group, randomised controlled trial - The Lancet Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease ( TRILOGY): a double-blind, parallel group, randomised controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/63480145-b6fd-4130-af26-95ad4355d876/gr3_lrg.jpg)
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease ( TRILOGY): a double-blind, parallel group, randomised controlled trial - The Lancet
![Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease ( TRILOGY): a double-blind, parallel group, randomised controlled trial - The Lancet Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease ( TRILOGY): a double-blind, parallel group, randomised controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2103f012-a6e0-4039-8a4a-631fe54c68f1/gr2.jpg)